Ir al menú de navegación principal Ir al contenido principal Ir al pie de página del sitio

Enfoque inicial del paciente con hemorragia alveolar difusa sin vasculitis pulmonar

Initial workup of the patient with diffuse alveolar hemorrhage without pulmonary vasculitis



Abrir | Descargar


Sección
Revisión de tema

Cómo citar
Enfoque inicial del paciente con hemorragia alveolar difusa sin vasculitis pulmonar.
rev. colomb. neumol. [Internet]. 2011 Dec. 20 [cited 2024 Nov. 22];23(4):118-23. Disponible en: https://doi.org/10.30789/rcneumologia.v23.n4.2011.229

Dimensions
PlumX
Licencia

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Azucena Martínez Caballero
    Andrea Córdoba Guzmán
      Robin Alonso Rada Escobar, MD.

        Azucena Martínez Caballero,

        Estudiante de Medicina, Universidad Militar Nueva Granada, Hospital Militar Central. Bogotá, Colombia.

        Andrea Córdoba Guzmán,

        Estudiante de Medicina, Universidad Militar Nueva Granada , Hospital Militar Central. Bogotá, Colombia.

        Robin Alonso Rada Escobar, MD.,

        Internista, Neumólogo, Jefe del Servicio de Medicina Interna, Hospital Militar Central. Coordinador Académico de Medicina Interna, Universidad Militar Nueva Granada. Bogotá, Colombia.

        La hemorragia alveolar difusa es una emergencia médica de instauración aguda, cuya aparición es secundaria a procesos fi siopatológicos dentro de la historia natural de un grupo de enfermedades que pueden cursar o no con vasculitis pulmonar. Tanto su reconocimiento como su diagnóstico oportunos permitirán establecer un tratamiento agresivo inmediato, evitar posibles complicaciones e incluso disminuir la alta tasa de mortalidad que engloba esta patología en la actualidad. En esta revisión se realiza un enfoque de cada una de las enfermedades asociadas a la hemorragia alveolar difusa sin vasculitis pulmonar, con especial énfasis en la fisiopatología.

        Visitas del artículo 1058 | Visitas PDF 4065


        Descargas

        Los datos de descarga todavía no están disponibles.
        1. Specks U. Diffuse alveolar hemorrhage syndromes. Current Opinion in Rheumatology 2001; 13 (1): 12-17.
        2. Ioachimescu OC, Stoller JK. Diffuse alveolar hemorrhage: diagnosing it and finding the cause. Cleve Clin J Med 2008; 75 (4): 258: 260-265.
        3. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest 2010; 137 (5): 1164-7.
        4. Newsome, Brandi R. Diffuse alveolar hemorrhage. Southern Medical Journal 2011; 104 (4): 269-274.
        5. McCabe C, Jones Q, Nikolopoulou A. Pulmonary-renal syndromes: An update for respiratory physicians. Respir Med 2011 Jun 17. [Epub ahead of print].
        6. Jara LJ, Vera-Lastra O, Calleja MC. Pulmonary-renal vasculitic disorders: differential diagnosis and management. Curr Rheumatol Rep 2003; 5 (2): 107-15.
        7. Hellmich B, Gross WL. Diffi cult to diagnose manifestations of vasculitis: does an interdisciplinary approach help? Best Pract Res Clin Rheumatol 2005; 19 (2): 243-61.
        8. Cordier JF, Cottin V. Alveolar hemorrhage in vasculitis: primary and secondary. Semin Respir Crit Care Med 2011; 32 (3): 310-21.
        9. Willms H, Gutjahr K. Diagnostics and therapy of idiopathic pulmonary hemosiderosis. Med Klin (Munich) 2007; 102 (6): 445-50.
        10. Oviedo Ramírez MI, Hop K, Carrera E, Soriano Rosas J. Idiopathic pulmonary haemosiderosis in a young adult. Autopsy findings Arch Bronconeumol 2010; 46 (10): 565-7. Epub 2010.Aug 13.
        11. Chen CH, Yang HB, Chiang SR, Wang PC. Idiopathic pulmonary hemosiderosis: favorable response to corticosteroids. J Chin Med Assoc 2008; 71 (8): 421-4.
        12. Chermiti BA Fatma, Chtourou A, Mahouchi R. Idiopathic pulmonary hemosiderosis in adult. Respiratory Medicine CME 2010; 3 (4): 238-240.
        13. Ioachimescu O. Idiopathic pulmonary hemosiderosis in adults. Clinical Pulmonary Medicine 2005; 12 (1): 16-25.
        14. Dolan CJ Jr, Srodes CH, Duffy FD. Idiopathic pulmonary hemosiderosis: electron microscopic, immunofl uorescent, and iron kinetic studies. Chest 1975; 68: 577-580.
        15. Corrin B, Jagusch M, Dewar A, et al. Fine structural changes in idiopathic pulmonary haemosiderosis. J Pathol 1987; 153: 249-256.
        16. Irwin RS, Cottrell TS, Hsu KC, et al. Idiopathic pulmonary hemosiderosis: an electron microscopic and immunofl uorescent study. Chest 1974; 65: 41-45.
        17. Blanco A, Solis P, Gómez S, et al. C1q-binding immune complexes and other immunological studies in children with pulmonary hemosiderosis. Allergol Immunopathol (Madr) 1984; 12: 37-44.
        18. Fullmer JJ, Langston C. Pulmonary capillaritis in children: a review of eight cases with comparison to other alveolar hemorrhage syndromes The Journal of Pediatrics 2005; 146 (3): 376-38.
        19. Le Clainche L, Le Bourgeois M, Fauroux B, et al. Long-term outcome of idiopathic pulmonary hemosiderosis in children. Medicine (Baltimore). 2000; 79: 318-326.
        20. Mayes DH, Guerrero ML A few good men: a Marine with hemoptysis and diarrhea. Idiopathic pulmonary hemosiderosis and celiac sprue. Chest 2008; 134 (3): 644-7.
        21. Khemiri M, Ouederni M. Screening for celiac disease in idiopathic pulmonary hemosiderosis. Gastroenterol Clin Biol 2008; 32 (8-9): 745-8.
        22. Centers for Disease Control and Prevention. Update: pulmonary hemorrhage/hemosiderosis among infants: Cleveland, Ohio, 1993–1996. JAMA 2000; 283: 1951-1953.
        23. Rao NR, Goodman LR. Smoking-related interstitial lung disease. Annals of Diagnostic Pathology 2008; 12 (6): 445-457.
        24. Deniz O, Ongürü O. Idiopathic pulmonary hemosiderosis in an adult patient responded well to corticosteroid therapy. Tuberk Toraks 2007; 55 (1): 77-82.
        25. Nuesslein TG, Teig N. Pulmonary haemosiderosis in infants and children. Paediatric Respiratory Reviews 2006; 7 (1): 45-48.
        26. Olser W. On the visceral manifestations of the erythema group of skin diseases. Am J Med Sci 2009; 338 (5): 396-408.
        27. Santos Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000; 118 (4): 1083-90.
        28. Badsha H, et al. Pulmonary hemorrhage in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism 2004; 33 (6): 414-42.
        29. Pego-Reigosa JM, Medeiros DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Practice & Research Clinical Rheumatology 2009; 23 (4): 469-480.
        30. Gómez-Román JJ. Diffuse alveolar hemorrhage. Archivos de Bronconeumología (English Edition). 2008; 44 (8): 428-436.
        31. Mahmoud GA, Gheith RE. Alveolar hemorrhage in systemic lupus erythematosus: An overview. The Egyptian Rheumatologist 2011; 33 (1): 1-1.
        32. O’Hara, Collin, Song, Joo Young. Goodpasture’s syndrome with negative serology. Pathology Case Reviews 2007; 12 (3): 109-112.
        33. Brandi R. Diffuse alveolar hemorrhage. Southern Medical Journal 2011; 104 (4): 269-274.
        34. Lê Quang C, Delèvaux I. Intra-alveolar haemorrhage without renal damage as the initial presenting feature of Goodpasture’s syndrome: case report and review of literature. Rev Med Interne 2008; 29 (12): 1038-42. Epub 2008 Jun 24.
        35. Cui Z, Zhao J, Jia XY. Clinical features and outcomes of antiglomerular basement membrane disease in older patients. Am J Kidney Dis 2011; 57 (4): 575-82. Epub 2010 Dec 18.
        36. Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture’s syndrome. South Med J 2002; 95 (12): 1411-8.
        37. Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 2000; 21 (3): 435-466.
        38. Huppmann AR. Drug-induced lung disease. Pathology Case Reviews 2007; 12 (3): 113-117.
        39. Castro CY. ARDS and diffuse alveolar damage: a pathologist’s perspective. Semin Thorac Cardiovasc Surg 2006; 18 (1): 13-9.
        40. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther 2001; 8 (2): 123-43.
        41. Ishida K, Seki R. Clinical aspect of diffuse alveolar hemorrhage syndrome. Nihon Kokyuki Gakkai Zasshi 2003; 41 (12): 851-6.
        42. Cohen S. Diffuse pulmonary hemorrhage: evolutionary ‘flaw’ or consequence of evolutionary progress? Am J Med Sci 2002; 323 (3): 130-9.
        43. O’Callaghan DS, Dorfmuller P. Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? Presse Med 2011; 40 (1 Pt 2): e65-78. Epub 2011 Jan 5.
        44. Barboza CE, Jardim CV. Pulmonary veno-occlusive disease: diagnostic and therapeutic alternatives. J Bras Pneumol 2008; 34 (9): 749-52.
        45. Lantuéjoul S, Sheppard MN. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30 (7): 850-7.
        46. Montani D, O’Callaghan DS, Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010; 104 (Suppl. 1): S23-32. Epub 2010 Apr 24.
        47. Sullivan A, Chmura K Pulmonary capillary hemangiomatosis: an immunohistochemical analysis of vascular remodeling. Eur J Med Res 2006; 11 (5): 187-93.
        48. Almagro P, Julià J. Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literatura. Medicine (Baltimore) 2002; 81 (6): 417-24.
        49. Kothari S. Pulmonary capillary hemangiomatosis. Circulation 2009; 120 (4): 352-354.
        50. Pacheco-Rodríguez G, Moss J. The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells. Crit Rev Immunol 2010; 30 (4): 387-94.
        51. Ansótegui Barrera E, Mancheño Franch N. Lymphangioleiomyomatosis. Archivos de Bronconeumología (English Edition) 2011; 47 (2): 85-93.
        52. Gao J, Zhu P. A clinicopathological analysis of pulmonary lymphangioleiomyomatosis. Zhongguo Fei Ai Za Zhi 2011; 14 (4): 378-82.
        53. Glasgow CG, Steagall WK. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 2010; 104 (Suppl. 1): S45-58.
        54. Díaz J, Calamia KT, Lee AS. Pulmonary vasculitis in the intensive care unit. J Intensive Care Med 2011; 26 (2): 88-104.
        Sistema OJS 3.4.0.7 - Metabiblioteca |